Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck KGaA has announced that its Merck Serono division signed a distribution agreement with Bristol-Myers Squibb for a portfolio of established pharmaceutical brands in Latin America.
Subscribe to our email newsletter
Under the terms of this agreement, Merck Serono acquires the exclusive rights to market, sell and distribute more than 30 prescription medicines, in particular in the CardioMetabolic Care therapeutic area, in seven Latin American countries.
The duration of the agreement is limited to an initial period of three years, with the possibility of further extension upon mutual agreement. The seven countries in Latin America covered by this in-licensing agreement are Argentina, Chile, Colombia, Ecuador, Panama, Peru and Venezuela.
The portfolio includes renowned brands such as Pravachol (pravastatin) for the treatment of elevated cholesterol levels and Monopril, an ACE-inhibitor used in the field of hypertension. While Merck Serono will be the exclusive distributor, Bristol-Myers Squibb will remain responsible for manufacturing of the medicines.
Franck Latrille, executive vice president commercial international at Merck Serono, said: “The established medicine brands of Bristol-Myers Squibb will complement our already strong portfolio, especially in cardiovascular diseases and in the field of primary care, so that we can offer added value to physicians and patients.”